Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL
Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.
Ibrutinib Induces Rapid, Durable Responses in Waldenström's Macroglobulinemia
The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory Waldenström's macroglobulinemia, and the responses to ibrutinib were durable.
Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma
The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.
Treating Precursor Disease May Stall Multiple Myeloma Progression
Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.
ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib
To gain insight into the studies being presented at the ASH Annual Meeting, we interviewed Marcel R.M. van den Brink, MD, PhD, on abstracts being presented by faculty at Memorial Sloan-Kettering Cancer Center.
Dr. Fanale on Brentuximab Vedotin in High-Risk ALCL
January 30th 2013Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma.
Dr. Zaks on the JAK2 Inhibitor SAR302503 in Myelofibrosis
January 21st 2013Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.
Dr. Smita Bhatia on Anthracycline-Related CHF
January 17th 2013Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.